有机化学 ›› 2024, Vol. 44 ›› Issue (9): 2682-2699.DOI: 10.6023/cjoc202403042 上一篇    下一篇

综述与进展

2021至2023年食品药品监督管理局(FDA)认证的含硫酰基药物

喻志岚a, 邹志玲a, 袁志文a, 曾春玲b, 彭丽芬a,*(), 许新华b, 唐子龙a,*(), 刘喜荣b,*()   

  1. a 湖南科技大学化学化工学院 理论有机化学与功能分子教育部重点实验室 精细聚合物可控制备及功能化应用湖南省重点实验室 湖南湘潭 411201
    b 湖南大学化学化工学院 化学生物传感与计量学国家重点实验室 长沙 410082
  • 收稿日期:2024-03-26 修回日期:2024-04-27 发布日期:2024-05-23
  • 通讯作者: 彭丽芬, 唐子龙, 刘喜荣
  • 基金资助:
    国家自然科学基金(22277025); 国家自然科学基金(21802040); 湖南省湖湘高层次人才聚集工程(创新团队)(2021RC5028); 湖南省自然科学基金(2022JJ80082); 湖南省自然科学基金(2022JJ30240)

Sulfuryl Group-Involved Drugs Approved by the Food and Drug Administration (FDA) from 2021 to 2023

Zhilan Yua, Zhiling Zoua, Zhiwen Yuana, Chunling Zengb, Lifen Penga(), Xinhua Xub, Zilong Tanga(), Xirong Liub()   

  1. a Laboratory of Theoretical Organic Chemistry and Functional Molecule of Ministry of Education, Hunan Provincial Key Laboratory of Controllable Preparation and Functional Application of Fine Polymers, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan 411201
    b State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082
  • Received:2024-03-26 Revised:2024-04-27 Published:2024-05-23
  • Contact: Lifen Peng, Zilong Tang, Xirong Liu
  • Supported by:
    National Natural Science Foundation of China(22277025); National Natural Science Foundation of China(21802040); Innovation Team of Huxiang High-Level Talent Gathering Engineering(2021RC5028); Natural Science Fund Project of Hunan Province(2022JJ80082); Natural Science Fund Project of Hunan Province(2022JJ30240)

有机砜类化合物具有独特的生物活性, 在制药和医疗等领域有重要的应用价值. 许多硫酰基类药物已获得食品药品监督管理局(FDA)认证. 2021年, 奥维昔巴特、氯马昔巴特以及贝组替凡均获得FDA认证, 可分别用于治疗原发性肝内胆汁淤积症(PFIC)、胆汁淤积性瘙痒症和肾透明细胞癌(ccRCC). 2022年, 阿布罗替尼、pyrukynd和伏诺拉生被FDA批准, 分别用于治疗特应性皮炎、多囊肾疾病(PKD)以及酸性相关性疾病. 2023年FDA批准了用于预防血流感染的牛磺罗定和肝素、用于治疗IgA肾病相关蛋白尿的司帕生坦, 以及用于治疗细菌性肺炎的舒巴坦/杜洛巴坦. 本综述详细介绍评述了上述硫酰基类药物的合成和治疗应用.

关键词: 砜类化合物, 药物, 食品药品监督管理局(FDA)认证

Organic sulfone compounds, exhibiting interesting bioactivities, were widely applied in the field of pharmaceutical and medicine. And numerous of sulfuryl group-involved drugs were approved by the Food and Drug Administration (FDA). Odevixibat, maralixibat chloride and belzutifan approved in 2021 could be applied in the treatment of progressive familial intrahepatic cholestasis (PFIC), cholestatic pruritus and clear cell renal cell carcinoma (ccRCC), respectively. In 2022, abrocitinib, pyrukynd and voquezna were approved for the treatment of atopic dermatitis, pyruvate kinase deficiency (PKD) and acid-related disorders, respectively. Defencath for preventing bloodstream infections, sparsentan for treatment of proteinuria related to IgA nephropathy, and xacduro for treatment of hospital-acquired bacterial pneumonia (HABP) were approved in 2023. In this review, the synthesis and therapies of these sulfuryl group-involved drugs approved from 2021 to 2023 are discussed in details.

Key words: sulfone, drugs, Food and Drug Administration (FDA) approval